BR0011152A - Péptidos inibidores da exocitosis neurónica, composições cosméticas e farmacêuticas que os contêm - Google Patents

Péptidos inibidores da exocitosis neurónica, composições cosméticas e farmacêuticas que os contêm

Info

Publication number
BR0011152A
BR0011152A BR0011152-0A BR0011152A BR0011152A BR 0011152 A BR0011152 A BR 0011152A BR 0011152 A BR0011152 A BR 0011152A BR 0011152 A BR0011152 A BR 0011152A
Authority
BR
Brazil
Prior art keywords
neuronic
cosmetic
pharmaceutical compositions
compositions containing
exocytosis
Prior art date
Application number
BR0011152-0A
Other languages
English (en)
Inventor
Gregorio Fernandez Ballester
Mercedes Llobregat Hernandez
Clara Blanes Mira
Rosa Planells Cases
Antonio Ferrer Montiel
Salvador Viniegra Bover
Anabel Gil Tebar
Luis Miguel Gutierrez Perez
Teresa Carbonell Castello
Enrique Perez Paya
Original Assignee
Lipotec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8308129&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0011152(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lipotec Sa filed Critical Lipotec Sa
Publication of BR0011152A publication Critical patent/BR0011152A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"PéPTIDOS INIBIDORES DA EXOCITOSIS NEURóNICA, COMPOSIçõES COSMéTICAS E FARMACêUTICAS QUE OS CONTêM". O péptido tem uma sequência de 3 a 30 amino-ácidos contíguos procedentes do extremo amino da proteína SNAP-25 e é útil como inibidor da exocitosis neurónica. As composições cosméticas e farmacêuticas compreendem o mencionado péptido, opcionalmente junto com um ou mais péptidos procedentes do extremo carboxilo da SNAP-25. As composições são adequadas para o tratamento das rugas faciais, da assimetria facial e de transtornos e alterações patológicas mediadas por uma exócitosis neurónica patológica.
BR0011152-0A 1999-04-23 2000-02-18 Péptidos inibidores da exocitosis neurónica, composições cosméticas e farmacêuticas que os contêm BR0011152A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009900844A ES2160485B1 (es) 1999-04-23 1999-04-23 Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
PCT/ES2000/000058 WO2000064932A1 (es) 1999-04-23 2000-02-18 Peptitos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen

Publications (1)

Publication Number Publication Date
BR0011152A true BR0011152A (pt) 2002-02-19

Family

ID=8308129

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0011152A BRPI0011152B8 (pt) 1999-04-23 2000-02-18 peptídeos inibidores da exocitose neuronal, mistura de peptídeos, composições cosméticas e farmacêuticas, utilização de um peptídeo, e, método para o tratamento cosmético em um ser humano das rugas faciais e/ou da assimetria facial
BR0011152-0A BR0011152A (pt) 1999-04-23 2000-02-18 Péptidos inibidores da exocitosis neurónica, composições cosméticas e farmacêuticas que os contêm

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0011152A BRPI0011152B8 (pt) 1999-04-23 2000-02-18 peptídeos inibidores da exocitose neuronal, mistura de peptídeos, composições cosméticas e farmacêuticas, utilização de um peptídeo, e, método para o tratamento cosmético em um ser humano das rugas faciais e/ou da assimetria facial

Country Status (12)

Country Link
US (2) US7015192B1 (pt)
EP (1) EP1180524B2 (pt)
JP (2) JP4363556B2 (pt)
AT (1) ATE338062T1 (pt)
AU (1) AU2672900A (pt)
BR (2) BRPI0011152B8 (pt)
CA (1) CA2370289C (pt)
DE (1) DE60030429T3 (pt)
DK (1) DK1180524T4 (pt)
ES (1) ES2160485B1 (pt)
PT (1) PT1180524E (pt)
WO (1) WO2000064932A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2160485B1 (es) * 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
PT1301213T (pt) 2000-07-21 2017-04-19 Revance Therapeutics Inc Sistemas de transporte biológico de múltiplos componentes
US7332567B2 (en) * 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
FR2846885B1 (fr) * 2002-11-13 2004-12-24 Oreal Utilisation d'une association de composants a effet synergique inhibiteur de canaux calciques pour prevenir ou traiter les ridules
US7071167B2 (en) 2002-11-13 2006-07-04 L'oreal Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines
JP2004323400A (ja) * 2003-04-23 2004-11-18 Mikimoto Pharmaceut Co Ltd 皮膚外用剤
JP2007527431A (ja) 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
WO2005084410A2 (en) 2004-03-03 2005-09-15 Essentia Biosystems, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
CA2584643C (en) * 2004-11-02 2013-01-29 Pentapharm Ag New, topically applicable actives against mimic and age-related wrinkles
JP2008531725A (ja) * 2005-03-03 2008-08-14 ルバンス セラピュティックス インク． オリゴペプチドの局所適用及び経皮送達のための組成物及び方法
BRPI0608249A2 (pt) 2005-03-03 2009-12-08 Revance Therapeutics Inc formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
ES2259928B1 (es) * 2005-04-08 2007-11-01 Lipotec, S.A. Composicion cosmetica o dermofarmaceutica que comprende peptidos derivados de encefalinas para reducir y/o eliminar arrugas faciales.
AU2006315117A1 (en) 2005-11-17 2007-05-24 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
EP2172210A1 (en) * 2005-12-23 2010-04-07 Partnership&Corp. Technology Transfer Synthetic peptides for use as inhibitors of neurotransmitter secretion
ES2322882B1 (es) * 2006-10-25 2010-04-22 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal.
EP1992332A1 (en) 2007-05-08 2008-11-19 Tupperware Products S.A. Cosmetic anti ageing skin care compositions
ES2356883B1 (es) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. Composición para el tratamiento del dolor y/o la inflamación.
IN2012DN01584A (pt) 2009-07-24 2015-06-05 Lipotec Sa
US20110305735A1 (en) * 2010-06-09 2011-12-15 Lipotec, S.A. Skin antiaging treatment
US20130078295A1 (en) * 2010-06-09 2013-03-28 Lipotec S.A. Skin antiaging treatment
ES2385683B1 (es) * 2010-10-18 2013-10-07 Bcn Peptides, S.A. Composiciones para el tratamiento del dolor y/o la inflamación.
WO2013070808A1 (en) 2011-11-07 2013-05-16 Feng Tian Peptide-based compounds as inhibitors of neurotransmitter secretion
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
MX356343B (es) 2012-04-13 2018-05-23 Lubrizol Advanced Mat Inc Compuestos que inhiben la exocitosis neuronal (ii).
ES2678793T3 (es) 2012-04-13 2018-08-17 Activen Composición cosmética que comprende un muconopéptido
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
US10149812B2 (en) 2012-04-13 2018-12-11 Activen Cosmetic composition comprising a muconopeptide
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
CA2928526A1 (en) 2013-11-01 2015-05-07 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
CA2965525A1 (en) 2014-10-31 2016-05-06 Lubrizol Advanced Materials, Inc. Thermoplastic polyurethane film for delivery of active agents to skin surfaces
CN104478991B (zh) * 2014-12-10 2018-06-19 深圳市维琪医药研发有限公司 一种新型多肽化合物及其制备方法和其医药应用
CN104829691B (zh) * 2015-05-19 2018-11-02 山西锦波生物医药股份有限公司 除皱短肽及其制备方法
EP3371238A1 (en) 2015-11-05 2018-09-12 Lubrizol Advanced Materials, Inc. Thermoformable dual network hydrogel compositions
ES2937382T3 (es) 2018-02-27 2023-03-28 Lipotrue S L Péptidos y composiciones para uso en cosmética y medicina
EP3807293A1 (en) 2018-06-13 2021-04-21 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Peptides having inhibitory activity on neuronal exocytosis
BR112021002381A2 (pt) 2018-08-10 2021-05-11 Lubrizol Advanced Materials, Inc. composto, combinação, composição, uso de um composto, e, método de tratamento e/ou cuidado cosmético, não terapêutico e/ou cuidado da pele, cabelo, unhas e/ou membranas mucosas de um sujeito
CA3116315A1 (en) 2018-10-16 2020-04-23 Glo Pharma, Inc. Nicotinic acetylcholine receptor peptide antagonist conotoxin compositions and related methods
MX2020014330A (es) * 2018-12-26 2021-03-09 Caregen Co Ltd Composicion para relajacion muscular.
EP4144337B1 (en) 2021-09-02 2024-08-07 Guangzhou Jiyan Cosmetics Technology Co. Ltd. Vitis vinifera cosmetic composition
CN113826764B (zh) * 2021-09-24 2024-07-12 江苏三仪生物工程有限公司 一种大豆小肽螯合铁的制备方法
EP4230638A1 (en) 2022-02-16 2023-08-23 Lipotrue, S.L. Peptides and compositions for use in cosmetics
WO2023161264A1 (en) 2022-02-23 2023-08-31 Prospera Biotech, S.L. Compositions for treating hyperhidrosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2334897A (en) * 1996-03-18 1997-10-10 Regents Of The University Of California, The Peptide inhibitors of neurotransmitter secretion by neuronal cells
ES2160485B1 (es) * 1999-04-23 2002-05-16 Lipotec Sa Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.

Also Published As

Publication number Publication date
WO2000064932A1 (es) 2000-11-02
PT1180524E (pt) 2007-01-31
ES2160485B1 (es) 2002-05-16
AU2672900A (en) 2000-11-10
EP1180524B2 (en) 2010-07-07
ES2160485A1 (es) 2001-11-01
CA2370289C (en) 2011-04-19
US7473679B2 (en) 2009-01-06
JP2002542777A (ja) 2002-12-17
US20060276392A1 (en) 2006-12-07
DK1180524T3 (da) 2006-12-11
JP4892037B2 (ja) 2012-03-07
EP1180524B1 (en) 2006-08-30
DE60030429T3 (de) 2012-01-12
ATE338062T1 (de) 2006-09-15
US7015192B1 (en) 2006-03-21
JP2009221223A (ja) 2009-10-01
DE60030429D1 (de) 2006-10-12
DK1180524T4 (da) 2010-10-25
JP4363556B2 (ja) 2009-11-11
DE60030429T2 (de) 2007-10-31
BRPI0011152B1 (pt) 2018-03-13
CA2370289A1 (en) 2000-11-02
BRPI0011152B8 (pt) 2022-05-10
EP1180524A1 (en) 2002-02-20

Similar Documents

Publication Publication Date Title
BR0011152A (pt) Péptidos inibidores da exocitosis neurónica, composições cosméticas e farmacêuticas que os contêm
PT1200105E (pt) Factor viii modificado
AR053063A2 (es) Proteina sustancialmente purificada y composicion farmaceutica que la comprende
BR0211641A (pt) Compostos anti-envelhecimento e de cura de ferimento
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
TW200833365A (en) Neuronal exocytosis inhibiting peptides
JP2018505890A5 (pt)
BR112018000660A2 (pt) peptídeos anti-inflamatórios e seu uso
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
HRP20110386T1 (hr) Sintetička sekvenca mecp2 za zamjensku proteinsku terapiju
BRPI0606445A2 (pt) inibidores de hipersecreÇço de mucina e mÉtodos de uso
Gildberg et al. Angiotensin I-converting enzyme inhibitory activity in a hydrolysate of proteins from Northern shrimp (Pandalus borealis) and identification of two novel inhibitory tri-peptides
ATE6251T1 (de) Acylpeptide und pharmazeutische praeparate davon, sowie deren herstellung und verwendung.
ES2052583T3 (es) Derivados de peptidos relacionados con el gel calcitonina.
BR0308860A (pt) Fator viii modificado
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
DK0707473T3 (da) Orale farmaceutiske præparater omfattende et protein eller et peptid, et antistof og polymerkugler
BR9712128A (pt) Métodos e composições para lipidização de moléculas hidrofìlicas
ES2170144T3 (es) Variantes que no se empalman de gp350/220.
BR9303903A (pt) Fator-4 de plaqueta modificado ou clivado e processo para sua preparaçao, formulaçao farmacêutica, composto e vetor de dna recombinante e célula hospedeira
BR0014803A (pt) Peptìdeo, composição farmacêutica, uso de um ou mais dos peptìdeos, e, composição de diagnóstico
ATE552271T1 (de) Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon
FR2569111B1 (fr) Nouveaux medicaments contenant des tripeptides
BRPI0308978B8 (pt) fragmentos de peptídeos, e, composições imunogênicas
ES2196864T3 (es) Secuencia antisentido para la inhibicion de la expresion de la molecula de adhesion icam-1.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: LIPOTEC, S.A. (ES)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/02/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 18/02/2020

B22E Other requirements [chapter 22.5 patent gazette]

Free format text: FORMULADA EXIGENCIA PARA ADEQUACAO OU CUMPRIMENTO DE DISPOSICOES LEGAIS NO PRAZO DE 60 (SESSENTA) DIAS DESTA DATA.

B16B Notification of grant cancelled [chapter 16.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 16.3 NA RPI NO 2629 DE 25/05/2021 POR TER SIDO INDEVIDA.

B21I Extinguishment of a patent or of a certificate of addition of invention: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 21.1 NA RPI NO 2630 DE 01/06/2021 POR TER SIDO INDEVIDA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: RETIFICACAO REF. RPI 2462, DE 13/03/2018. PRAZO DE VALIDADE: 10 ANOS CONTADOS A PARTIR DE 13/03/2018, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME A ADI 5.529/DF, COM APOSTILAMENTO DO PRAZO DE VALIDADE DA PROTECAO DA MATERIA RELATIVA A PRODUTOS E PROCESSOS FARMACEUTICOS E EQUIPAMENTOS E/OU MATERIAIS DE USO EM SAUDE, PARA APLICACAO EM HUMANOS.